This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
Leggi →
Maggio 2024